Hey tada, despite my poorly worded previous post I do I know that the data RVX receives is blinded. My point was that the summarized “gross” data and trends in the data for people in the trial can still be compared to statistical norms for the general population of like patients suffering from CVD. Because the trial is 1:1 any positive trends noted might lead to an educated guess that positive trends are due to drug. A lot can likely be learned by this type of comparison. Who knows perhaps if multiple comparative group data points were positive enough as compared to norms it might in fact lead the company to continue patients past 24 months (as RVX is doing) thereby expanding the number of patient years incorporated in the trial and just dispense with the SSRA. Obviously just one potential avenue.  I guess we shall see with time.